Filing Flows › Emergent BioSolutions (EBS) › Capital expenditures
Emergent BioSolutions (EBS) capital expenditures by quarter
Emergent BioSolutions' capital expenditures were $3.3M in Q3 2026 (third quarter 2026), +57% from Q2 2026. Over the last 4 quarters it ranged from $2.1M (Q2 2026) to $3.9M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.3M | +57% | — |
| Q2 2026 | $2.1M | -46% | -28% |
| Q4 2025 | $3.9M | +34% | — |
| Q2 2025 | $2.9M | — | — |
Q3 2026 at a glance
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
What is Emergent BioSolutions' capital expenditures?
Emergent BioSolutions' capital expenditures were $3.3M in Q3 2026 (third quarter 2026), +57% from Q2 2026.
How has Emergent BioSolutions' capital expenditures changed?
Over the last 4 quarters it ranged from $2.1M (Q2 2026) to $3.9M (Q4 2025).